© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
Michael R. Abern, MD | Authors
Articles
Counterpoint: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?
June 19, 2019
In this Point/Counterpoint, Drs. Madueke and Abern argue that active surveillance should not currently be considered for patients with intermediate-risk prostate cancer.
Evolution of the Concept of Focal Therapy for Prostate Cancer
January 15, 2013
In this review we focus on the recent evolution of the concept of focal therapy and the potential applications of this management approach within an array of options currently available for patients with localized prostate cancer.